Candel Therapeutics (CADL) stockholders elect directors, ratify KPMG at 2026 meeting
Rhea-AI Filing Summary
Candel Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 23, 2026. As of April 24, 2026, there were 73,270,239 outstanding shares of voting common stock entitled to vote at the meeting.
Stockholders elected four Class II directors to serve until the 2029 annual meeting: Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci. Support ranged from 24,897,348 to 31,591,618 votes "for," with broker non-votes of 22,175,525 for each nominee.
Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 53,543,020 votes for, 238,508 against, and 87,967 abstentions. No other matters were submitted for a vote.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding eligible to vote: 73,270,239 shares
Votes for KPMG auditor ratification: 53,543,020 votes
Votes against KPMG auditor ratification: 238,508 votes
+4 more
7 metrics
Shares outstanding eligible to vote
73,270,239 shares
Voting common stock as of record date April 24, 2026
Votes for KPMG auditor ratification
53,543,020 votes
Proposal 2, fiscal year ending December 31, 2026
Votes against KPMG auditor ratification
238,508 votes
Proposal 2, Annual Meeting on June 23, 2026
Abstentions on auditor ratification
87,967 votes
Proposal 2, independent registered public accounting firm
Votes for Paul B. Manning
31,591,618 votes
Election as Class II director under Proposal 1
Votes withheld for Edward J. Benz, Jr., M.D.
6,796,622 votes
Election as Class II director, Proposal 1
Broker non-votes for director elections
22,175,525 votes
Each Class II director nominee under Proposal 1
Key Terms
Annual Meeting of Stockholders, record date, Class II directors, broker non-votes, +1 more
5 terms
Annual Meeting of Stockholders financial
"held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 23, 2026"
record date financial
"As of April 24, 2026, the record date for the Annual Meeting"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
Class II directors financial
"to elect four Class II directors, Edward J. Benz, Jr., M.D., Paul B. Manning"
broker non-votes financial
"The votes cast at the Annual Meeting were as follows ... Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
FAQ
What did Candel Therapeutics (CADL) stockholders vote on at the 2026 Annual Meeting?
Stockholders voted on electing four Class II directors and ratifying KPMG LLP as independent registered public accounting firm for 2026. These proposals were described in the company’s definitive proxy statement filed April 29, 2026, and both items received the required stockholder approvals.
Who was elected to Candel Therapeutics (CADL) board as Class II directors in 2026?
Stockholders elected Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci as Class II directors. They will serve until the 2029 annual meeting and until their successors are duly elected and qualified, subject to earlier death, resignation, or removal.
What were the vote results for Candel Therapeutics (CADL) auditor ratification in 2026?
The appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026 received 53,543,020 votes for, 238,508 votes against, and 87,967 abstentions. This outcome reflects stockholder ratification of KPMG’s role as the company’s external auditor for that fiscal year.
How strong was support for Candel Therapeutics (CADL) director nominee Paul B. Manning in 2026?
Director nominee Paul B. Manning received 31,591,618 votes for and 102,352 votes withheld, with 22,175,525 broker non-votes. These results show that a large majority of votes cast by stockholders present or represented at the meeting supported his election to the board.
When was Candel Therapeutics (CADL) 2026 Annual Meeting held and what else was voted?
The Annual Meeting took place on June 23, 2026. Besides electing four Class II directors, stockholders voted on ratifying KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. No other matters were submitted for a vote at this meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
